This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Orlistat

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • indication - 'in conjunction with a mildly hypocaloric diet for the treatment of obese patients with a body mass index (BMI) greater or equal to 30 kg/m^2, or overweight patients (BMI >= 28 kg/m^2) with associated risk factors'
    • orlistat should be prescribed only as part of an overall plan for managing obesity in adults who meet one of the following criteria (1):
      • a BMI of 28.0 kg/m2 or more with associated risk factors
      • a BMI of 30.0 kg/m2 or more
    • therapy should be continued beyond 3 months only if the person has lost at least 5% of their initial body weight since starting drug treatment
    • the decision to use drug treatment for longer than 12 months (usually for weight maintenance) should be made after discussing potential benefits and limitations with the patient
    • the coprescribing of orlistat with other drugs aimed at weight reduction is not recommended
  • the European Commission has approved an extension to the prescribing licence for orlistat - this has lifted the maximum two year treatment limit and allows orlistat to be prescribed indefinitely where effective for patients who are overweight and obese (2)

Reference:

  1. NICE (November 2014). Obesity Guidance
  2. Xenical - product announcement. MIMS (March 2004).

Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.